CLINICAL TRIALS PROFILE FOR DROSPIRENONE; ESTETROL

All Clinical Trials for Drospirenone; Estetrol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02817828 ↗	E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study	Completed	PRA Health Sciences	Phase 3	2016-06-01	The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.
NCT02817828 ↗	E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study	Completed	Estetra	Phase 3	2016-06-01	The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.
NCT02817841 ↗	E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study	Completed	PRA Health Sciences	Phase 3	2016-08-30	The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.
NCT02817841 ↗	E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study	Completed	Estetra	Phase 3	2016-08-30	The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.
NCT02852681 ↗	Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers	Completed	Estetra	Phase 1	2015-08-01	This single-center, open-label, randomized, balanced, single-dose, two-treatment, two-period, two-sequence crossover study was conducted under medical supervision in 28 healthy female volunteers.

Clinical Trial Conditions for Drospirenone; Estetrol

Condition Name

Condition Name for Drospirenone; Estetrol
Intervention	Trials
Contraception	7
Cervical Mucus	2
Serum Hormonal Profile	2
Ultrasound Finding: Ovulation Inhibition, Ovarian Activities	2

Condition MeSH

Condition MeSH for Drospirenone; Estetrol
Intervention	Trials
Uterine Diseases	2
Endometriosis	1

Clinical Trial Locations for Drospirenone; Estetrol

Trials by Country

Trials by Country for Drospirenone; Estetrol
Location	Trials
Italy	2
Netherlands	2
Thailand	2
Canada	2
Belgium	1

Trials by US State

Trials by US State for Drospirenone; Estetrol
Location	Trials
Pennsylvania	1

Clinical Trial Progress for Drospirenone; Estetrol

Clinical Trial Phase

Clinical Trial Phase for Drospirenone; Estetrol
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	1
Phase 3	3

Clinical Trial Status

Clinical Trial Status for Drospirenone; Estetrol
Clinical Trial Phase	Trials
Completed	12
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for Drospirenone; Estetrol

Sponsor Name

Sponsor Name for Drospirenone; Estetrol
Sponsor	Trials
Estetra	9
PRA Health Sciences	2
University of Roma La Sapienza	2

Sponsor Type

Sponsor Type for Drospirenone; Estetrol
Sponsor	Trials
Industry	12
Other	7

Drospirenone; Estetrol Market Analysis and Financial Projection

Last updated: April 27, 2026

Drosperinone + Estetrol: What the Clinical and Market Readout Says Now

What is the current clinical development status for drospirenone + estetrol?

No complete, trial-by-trial clinical trials update can be produced from the information provided in this prompt. A proper update requires a verified list of active and completed studies (phase, design, endpoints, sites/regions, enrollment, status dates, and results releases) and those data are not present.

What does the market analysis indicate for drospirenone + estetrol?

No complete, source-backed market analysis and projection can be produced from the information provided in this prompt. A proper market readout requires at minimum: labeled indications, approved geographies, price and reimbursement context, competitive benchmark volumes and pricing, and forecast inputs. None are present.

What is the defensible market projection for drospirenone + estetrol?

No defensible forecast can be produced from the information provided in this prompt. Forecasting requires baseline market sizing, expected launch timing by territory, uptake curves, competitive displacement assumptions, and payer constraints, none of which are supplied.

Key Takeaways

• A clinical trials update for drospirenone + estetrol requires verified study-level information (phase, status, endpoints, and results). That is not available in the prompt.
• A market analysis and forecast require approved-label scope, geography, pricing/reimbursement context, competitive benchmarks, and forecast drivers. That is not available in the prompt.
• No actionable numbers or projections can be stated without a cited evidence trail.

FAQs

1. Can you provide a phase-by-phase clinical trials timeline for drospirenone + estetrol from the prompt?
   Not without verified trial records (phase, status, dates, and results), which are not included.

2. What territories are covered by drospirenone + estetrol approvals?
   Territory coverage is not provided in the prompt.

3. What is the primary competitive landscape for drospirenone + estetrol?
   Competitive benchmarks are not provided in the prompt.

4. What is the expected launch timeline and revenue ramp?
   Launch and ramp assumptions are not provided in the prompt.

5. What drivers should a forecast model use for this combination?
   Forecast drivers (payer mix, uptake rates, dosing regimen adoption, and displacement) are not provided in the prompt.

References (APA)

[1] No cited sources were available from the provided prompt.